封面
市場調查報告書
商品編碼
1764079

骨質疏鬆症藥物市場-全球產業規模、佔有率、趨勢、機會和預測(按給藥途徑、藥物類型、地區和競爭細分,2020-2030 年)

Osteoporosis Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Route of Administration, By Drug Type, By Region and Competition, 2020-2030F

出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024年,全球骨質疏鬆症藥物市場規模達134億美元,預計2030年將達到169.1億美元,複合年成長率為4.15%。骨質疏鬆症是一種漸進性骨骼疾病,以低骨量和高骨折風險為特徵,主要影響停經後女性和老年人。隨著全球預期壽命的延長,骨質疏鬆症及其相關骨折的盛行率也隨之上升,推動了對藥物治療的強勁需求。

市場概覽
預測期 2026-2030
2024年市場規模 134億美元
2030年市場規模 169.1億美元
2025-2030 年複合年成長率 4.15%
成長最快的領域 口服
最大的市場 北美洲

市場涵蓋多種藥物類別,包括雙磷酸鹽類藥物、選擇性雌激素受體調節劑 (SERM)、RANK 配體抑制劑、降鈣素和副甲狀腺素類似物。雙磷酸鹽類藥物,例如阿崙膦酸鹽和利塞膦酸鹽,因其價格低廉且臨床應用廣泛,歷來佔據主導地位。儘管市場前景依然看好,但諸如新型生物製劑的高成本、對長期副作用的擔憂以及依從性問題等挑戰,仍在阻礙其更廣泛地應用。

關鍵市場促進因素

醫療保健產業的成長

主要市場挑戰

治療費用高昂

主要市場趨勢

家庭骨質疏鬆症照護的興起

目錄

第 1 章:產品概述

第2章:研究方法

第3章:執行摘要

第4章:COVID-19 對全球骨質疏鬆症藥物市場的影響

第5章:全球骨質疏鬆症藥物市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 依給藥途徑(口服、注射、其他)
    • 依藥物類型(副甲狀腺素治療、雙磷酸鹽、降鈣素、選擇性雌激素受體調節劑、其他)
    • 按地區
    • 按公司分類(2024)
  • 市場地圖

第6章:北美骨質疏鬆症藥物市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美:國家分析
    • 美國
    • 墨西哥
    • 加拿大

第7章:歐洲骨質疏鬆症藥物市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲:國家分析
    • 法國
    • 德國
    • 英國
    • 義大利
    • 西班牙

第8章:亞太地區骨質疏鬆症藥物市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 亞太地區:國家分析
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲

第9章:南美骨質疏鬆症藥物市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲:國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第10章:中東與非洲骨質疏鬆症藥物市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA:國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 11 章:市場動態

  • 驅動程式
  • 挑戰

第 12 章:市場趨勢與發展

  • 合併與收購(如有)
  • 產品發布(如有)
  • 最新動態

第13章:干擾:衝突、流行病與貿易壁壘

第 14 章:全球骨質疏鬆症藥物市場:SWOT 分析

第 15 章:波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 顧客的力量
  • 替代產品的威脅

第 16 章:競爭格局

  • Eli Lilly and Company
  • Pfizer Inc.
  • F. Hoffmann-La Roche Ltd
  • Teva Pharmaceutical Industries Ltd.
  • GlaxoSmithKline plc.
  • Novartis International AG
  • Merck & Co. Inc.
  • Amgen Inc.
  • Radius Health Inc.
  • Actavis PLC

第 17 章:策略建議

第18章調查會社について,免責事項

簡介目錄
Product Code: 5081

The Global Osteoporosis Drugs Market was valued at USD 13.40 Billion in 2024 and is projected to reach USD 16.91 Billion by 2030, growing at a CAGR of 4.15%. Osteoporosis, a progressive skeletal disorder marked by low bone mass and heightened fracture risk, predominantly affects postmenopausal women and the elderly. As global life expectancy rises, so too does the prevalence of osteoporosis and associated fractures, driving strong demand for pharmacological therapies.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 13.40 Billion
Market Size 2030USD 16.91 Billion
CAGR 2025-20304.15%
Fastest Growing SegmentOral
Largest MarketNorth America

The market spans various drug categories, including bisphosphonates, SERMs, RANK ligand inhibitors, calcitonin, and parathyroid hormone analogs. Bisphosphonates, such as alendronate and risedronate, have historically dominated due to their affordability and widespread clinical use. While the market outlook remains favorable, challenges such as high costs associated with newer biologic treatments, concerns regarding long-term side effects, and adherence issues continue to temper broader adoption.

Key Market Drivers

Growth in Healthcare Industry

The global healthcare sector's continued growth plays a pivotal role in advancing the osteoporosis drugs market. With annual sales surpassing USD 4 trillion, key healthcare segments include pharmaceuticals and biotechnology, generating nearly USD 850 billion, and medical diagnostics and technology, contributing over USD 400 billion. As healthcare infrastructure expands and access improves worldwide, there is a heightened focus on early detection and effective treatment of chronic age-related conditions like osteoporosis. This rising awareness and investment are translating into increased demand for medications aimed at enhancing bone density and minimizing fracture risk.

Key Market Challenges

High Cost of Therapy

The substantial cost of osteoporosis therapy presents a major barrier to widespread access, particularly in lower-income and underinsured populations. Although biologics such as denosumab and parathyroid hormone analogs like teriparatide offer strong efficacy for high-risk patients, these treatments are priced significantly higher than conventional options like bisphosphonates. This pricing disparity limits affordability, especially in regions where public healthcare systems are underfunded or health insurance coverage is insufficient. The long-term nature of osteoporosis treatment further intensifies the economic burden for patients and providers alike.

Key Market Trends

Rise in Home-Based Osteoporosis Care

The growing shift toward home-based osteoporosis management is reshaping the landscape of care delivery. In May 2023, the International Osteoporosis Foundation (IOF) launched the Build Better Bones platform-a digital resource designed to support individuals and caregivers with practical tools for strengthening bones and preventing fragility fractures. This trend reflects a broader move toward patient-centric care models, particularly for elderly or mobility-limited patients.

By facilitating remote education, personalized exercise routines, and nutritional guidance, home-based care helps improve adherence to long-term drug regimens and enhances clinical outcomes. It also reduces pressure on healthcare facilities, offering a more accessible and cost-effective approach to chronic disease management.

Key Market Players

  • Eli Lilly and Company
  • Pfizer Inc.
  • F. Hoffmann-La Roche Ltd
  • Teva Pharmaceutical Industries Ltd.
  • GlaxoSmithKline plc.
  • Novartis International AG
  • Merck & Co. Inc.
  • Amgen Inc.
  • Radius Health Inc.
  • Actavis PLC

Report Scope

In this report, the Global Osteoporosis Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Osteoporosis Drugs Market, By Route of Administration:

  • Oral
  • Injectables
  • Others

Osteoporosis Drugs Market, By Drug Type:

  • Parathyroid Hormone Therapy
  • Bisphosphonates
  • Calcitonin
  • Selective Estrogen Receptor Modulators
  • Others

Osteoporosis Drugs Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Osteoporosis Drugs Market.

Available Customizations

Global Osteoporosis Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, and Trends

4. Impact of COVID-19 on Global Osteoporosis Drugs Market

5. Global Osteoporosis Drugs Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Route of Administration (Oral, Injectables, Others)
    • 5.2.2. By Drug Type (Parathyroid Hormone Therapy, Bisphosphonates, Calcitonin, Selective Estrogen Receptor Modulators, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2024)
  • 5.3. Market Map

6. North America Osteoporosis Drugs Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Route of Administration
    • 6.2.2. By Drug Type
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Osteoporosis Drugs Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Route of Administration
        • 6.3.1.2.2. By Drug Type
    • 6.3.2. Mexico Osteoporosis Drugs Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Route of Administration
        • 6.3.2.2.2. By Drug Type
    • 6.3.3. Canada Osteoporosis Drugs Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Route of Administration
        • 6.3.3.2.2. By Drug Type

7. Europe Osteoporosis Drugs Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Route of Administration
    • 7.2.2. By Drug Type
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Osteoporosis Drugs Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Route of Administration
        • 7.3.1.2.2. By Drug Type
    • 7.3.2. Germany Osteoporosis Drugs Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Route of Administration
        • 7.3.2.2.2. By Drug Type
    • 7.3.3. United Kingdom Osteoporosis Drugs Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Route of Administration
        • 7.3.3.2.2. By Drug Type
    • 7.3.4. Italy Osteoporosis Drugs Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Route of Administration
        • 7.3.4.2.2. By Drug Type
    • 7.3.5. Spain Osteoporosis Drugs Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Route of Administration
        • 7.3.5.2.2. By Drug Type

8. Asia Pacific Osteoporosis Drugs Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Route of Administration
    • 8.2.2. By Drug Type
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Osteoporosis Drugs Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Route of Administration
        • 8.3.1.2.2. By Drug Type
    • 8.3.2. India Osteoporosis Drugs Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Route of Administration
        • 8.3.2.2.2. By Drug Type
    • 8.3.3. South Korea Osteoporosis Drugs Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Route of Administration
        • 8.3.3.2.2. By Drug Type
    • 8.3.4. Japan Osteoporosis Drugs Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Route of Administration
        • 8.3.4.2.2. By Drug Type
    • 8.3.5. Australia Osteoporosis Drugs Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Route of Administration
        • 8.3.5.2.2. By Drug Type

9. South America Osteoporosis Drugs Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Route of Administration
    • 9.2.2. By Drug Type
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Osteoporosis Drugs Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Route of Administration
        • 9.3.1.2.2. By Drug Type
    • 9.3.2. Argentina Osteoporosis Drugs Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Route of Administration
        • 9.3.2.2.2. By Drug Type
    • 9.3.3. Colombia Osteoporosis Drugs Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Route of Administration
        • 9.3.3.2.2. By Drug Type

10. Middle East and Africa Osteoporosis Drugs Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Route of Administration
    • 10.2.2. By Drug Type
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Osteoporosis Drugs Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Route of Administration
        • 10.3.1.2.2. By Drug Type
    • 10.3.2. Saudi Arabia Osteoporosis Drugs Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Route of Administration
        • 10.3.2.2.2. By Drug Type
    • 10.3.3. UAE Osteoporosis Drugs Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Route of Administration
        • 10.3.3.2.2. By Drug Type

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Disruptions : Conflicts, Pandemics and Trade Barriers

14. Global Osteoporosis Drugs Market: SWOT Analysis

15. Porters Five Forces Analysis

  • 15.1. Competition in the Industry
  • 15.2. Potential of New Entrants
  • 15.3. Power of Suppliers
  • 15.4. Power of Customers
  • 15.5. Threat of Substitute Products

16. Competitive Landscape

  • 16.1. Eli Lilly and Company
    • 16.1.1. Business Overview
    • 16.1.2. Company Snapshot
    • 16.1.3. Products & Services
    • 16.1.4. Financials (As Reported)
    • 16.1.5. Recent Developments
    • 16.1.6. Key Personnel Details
    • 16.1.7. SWOT Analysis
  • 16.2. Pfizer Inc.
  • 16.3. F. Hoffmann-La Roche Ltd
  • 16.4. Teva Pharmaceutical Industries Ltd.
  • 16.5. GlaxoSmithKline plc.
  • 16.6. Novartis International AG
  • 16.7. Merck & Co. Inc.
  • 16.8. Amgen Inc.
  • 16.9. Radius Health Inc.
  • 16.10. Actavis PLC

17. Strategic Recommendations

18. About Us & Disclaimer